Scott Wolchko, Fate Therapeutics CEO

Fate's close­ly watched stem cell-de­rived NK pro­gram rais­es red flag over dura­bil­i­ty of re­sponse

At the cut­ting edge of on­col­o­gy re­search, biotechs like Fate Ther­a­peu­tics are look­ing for ways to craft next-gen cell ther­a­pies with­out re­ly­ing on pa­tients’ own cells. An ear­ly peek at the com­pa­ny’s clin­i­cal da­ta looks promis­ing, but will iffy dura­bil­i­ty re­sults prove a road­block?

Fate on Thurs­day re­vealed an ear­ly cut of Phase I da­ta for its FT596 and FT516 in­duced pluripo­tent stem cell-de­rived nat­ur­al killer cell pro­grams that re­vealed po­ten­tial red flags on one of the ther­a­pies’ dura­bil­i­ty over time.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.